Nautilus Biotechnology Net Worth

Nautilus Biotechnology Net Worth Breakdown

  NAUT
The net worth of Nautilus Biotechnology is the difference between its total assets and liabilities. Nautilus Biotechnology's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Nautilus Biotechnology's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Nautilus Biotechnology's net worth can be used as a measure of its financial health and stability which can help investors to decide if Nautilus Biotechnology is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Nautilus Biotechnology stock.

Nautilus Biotechnology Net Worth Analysis

Nautilus Biotechnology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Nautilus Biotechnology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Nautilus Biotechnology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Nautilus Biotechnology's net worth analysis. One common approach is to calculate Nautilus Biotechnology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Nautilus Biotechnology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Nautilus Biotechnology's net worth. This approach calculates the present value of Nautilus Biotechnology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Nautilus Biotechnology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Nautilus Biotechnology's net worth. This involves comparing Nautilus Biotechnology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Nautilus Biotechnology's net worth relative to its peers.
To determine if Nautilus Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nautilus Biotechnology's net worth research are outlined below:
Nautilus Biotechnology generated a negative expected return over the last 90 days
Nautilus Biotechnology has some characteristics of a very speculative penny stock
Nautilus Biotechnology has high historical volatility and very poor performance
Nautilus Biotechnology has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (70.78 M) with profit before overhead, payroll, taxes, and interest of 0.
Nautilus Biotechnology currently holds about 299.34 M in cash with (59.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 33.0% of the company outstanding shares are owned by corporate insiders
Nautilus Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nautilus Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nautilus Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
22nd of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Nautilus Biotechnology's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 126.14 M.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nautilus Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nautilus Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nautilus Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Akinsanya Karen 23 hours ago
Acquisition by Akinsanya Karen of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3
 
Sujal Patel 2 days ago
Acquisition by Sujal Patel of 23933 shares of Nautilus Biotechnology at 0.9982 subject to Rule 16b-3
 
Sujal Patel 3 days ago
Acquisition by Sujal Patel of 53300 shares of Nautilus Biotechnology at 0.9949 subject to Rule 16b-3
 
Nazem Farzad six days ago
Acquisition by Nazem Farzad of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3
 
Akinsanya Karen over a week ago
Acquisition by Akinsanya Karen of 14411 shares of Nautilus Biotechnology subject to Rule 16b-3
 
Nelson Nicholas A. over a week ago
Acquisition by Nelson Nicholas A. of 160000 shares of Nautilus Biotechnology at 1.24 subject to Rule 16b-3
 
Nelson Nicholas A. over two weeks ago
Acquisition by Nelson Nicholas A. of 160000 shares of Nautilus Biotechnology at 1.24 subject to Rule 16b-3
 
Gwen Weld over three months ago
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.0 subject to Rule 16b-3
 
Subra Sankar over three months ago
Acquisition by Subra Sankar of 140000 shares of Nautilus Biotechnology at 3.78 subject to Rule 16b-3
 
Sujal Patel over three months ago
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
 
Gwen Weld over three months ago
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
 
Sujal Patel over three months ago
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
Nautilus Biotechnology time-series forecasting models is one of many Nautilus Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nautilus Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Nautilus Biotechnology Earnings per Share Projection vs Actual

Nautilus Biotechnology Corporate Management

Gwen WeldChief OfficerProfile
Parag MallickChief CoFounderProfile
Sujal PatelCEO, CoFounderProfile
Mary GodwinSenior OperationsProfile
Chris BlessingtonVice CommunicationsProfile
Subra SankarSenior DevelopmentProfile
Kentaro SuzukiChief OfficerProfile

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.